Down syndrome (DS) children have a unique genetic susceptibility to develop leukemia, in particular, acute megakaryocytic leukemia (AMkL) associated with somatic GATA1 mutations. The study of this genetic susceptibility with the use of DS as a model of leukemogenesis has broad applicability to the understanding of leukemia in children overall. On the basis of the role of GATA1 mutations in DS AMkL, we analyzed the mutational spectrum of GATA1 mutations to begin elucidating possible mechanisms by which these sequence alterations arise. Mutational analysis revealed a predominance of small insertion/deletion, duplication, and base substitution mutations, including G:C>T:A, G:C>A:T, and A:T>G:C. This mutational spectrum points to potential oxidative stress and aberrant folate metabolism secondary to genes on chromosome 21 (eg, cystathionine-beta-synthase, superoxide dismutase) as potential causes of GATA1 mutations. Furthermore, DNA repair capacity evaluated in DS and non-DS patient samples provided evidence that the base excision repair pathway is compromised in DS tissues, suggesting that inability to repair DNA damage also may play a critical role in the unique susceptibility of DS children to develop leukemia. A model of leukemogenesis in DS is proposed in which mutagenesis is driven by cystathionine-beta-synthase overexpression and altered folate homeostasis that becomes fixed as the ability to repair DNA damage is compromised.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756130PMC
http://dx.doi.org/10.1182/blood-2008-11-190330DOI Listing

Publication Analysis

Top Keywords

gata1 mutations
16
mutational spectrum
12
spectrum gata1
8
genetic susceptibility
8
develop leukemia
8
model leukemogenesis
8
repair dna
8
dna damage
8
gata1
5
mutations
5

Similar Publications

Matrix Gla protein (MGP) is a vitamin K-dependent γ-carboxylated protein that was initially identified as a physiological inhibitor of ectopic calcification, primarily affecting cartilage and the vascular system. Mutations in the gene were found to be responsible for the Keutel syndrome, a condition characterized by abnormal calcifications in the cartilage, lungs, brain, and vascular system. has been shown to be dysregulated in several tumors, including cervical, ovarian, urogenital, and breast cancers.

View Article and Find Full Text PDF

Transient abnormal myelopoiesis (TAM) generally affects newborns with Down syndrome and is associated with constitutional trisomy 21 and a somatic GATA1 mutation. Here we describe a case of TAM which evolved after umbilical cord blood transplantation (UCBT), whose origin was identified as a GATA1 mutation-harboring clone in umbilical cord blood (UCB) by detailed genetic analyses. A 58-year-old male who received UCBT for peripheral T-cell lymphoma presented progressive anemia and thrombocytopenia, and leukocytosis with blast cells in the peripheral blood (PB).

View Article and Find Full Text PDF
Article Synopsis
  • - Gestational Trophoblastic Neoplasia (GTN) is a serious tumor arising from trophoblastic cells, with the study showing increased levels of DLX4 in GTN tissues and cell lines.
  • - Bioinformatic analysis indicates that DLX4 is often overexpressed in various cancers and correlates with poor survival rates and immune-related genes.
  • - Although manipulating DLX4 levels does not change GTN cell growth, it influences PD-L1 expression through GATA1, suggesting DLX4 could be a potential target for cancer treatment.
View Article and Find Full Text PDF
Article Synopsis
  • Transient abnormal myelopoiesis (TAM) in neonates with Down syndrome (DS) presents similarly to acute megakaryoblastic leukemia but usually resolves on its own within months postpartum.
  • Some cases of TAM can lead to severe health issues, impacting the patient's prognosis negatively.
  • An autopsy of a stillborn female with TAM and DS revealed GATA1s protein expression in unusual immature megakaryocytes, indicating that placental tissue can be useful for diagnosing TAM histologically.
View Article and Find Full Text PDF

Regulated GATA1 expression as a universal gene therapy for Diamond-Blackfan anemia.

Cell Stem Cell

November 2024

Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Howard Hughes Medical Institute, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address:

Gene therapy using hematopoietic stem and progenitor cells is altering the therapeutic landscape for patients with hematologic, immunologic, and metabolic disorders but has not yet been successfully developed for individuals with the bone marrow failure syndrome Diamond-Blackfan anemia (DBA). More than 30 mutations cause DBA through impaired ribosome function and lead to inefficient translation of the erythroid master regulator GATA1, providing a potential avenue for therapeutic intervention applicable to all patients with DBA, irrespective of the underlying genotype. Here, we report the development of a clinical-grade lentiviral gene therapy that achieves erythroid lineage-restricted expression of GATA1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!